ライフサイエンスコーパス: treatment protocol

1 col) or after ileitis was fully established (treatment protocol).

2 olone, remained active when tested in a post-treatment protocol.

3 se rates using a fixed-interval rituximab re-treatment protocol.

4 are being used more frequently as part of a treatment protocol.

5 ecologic Oncology Group randomized phase III treatment protocol.

6 her IM862 or EMAP-II was included in the PDT treatment protocol.

7 ystem (CNS) relapse, with stratification for treatment protocol.

8 identify the toxicities associated with this treatment protocol.

9 uride or insulin according to an intensified treatment protocol.

10 phy in a dose-dependent manner over a 14-day treatment protocol.

11 including certain antioxidant agents in the treatment protocol.

12 nocarcinoma were enrolled on a multimodality treatment protocol.

13 to recover from depression in a standardized treatment protocol.

14 he Ca2+ transient were not influenced by any treatment protocol.

15 ompletion of the acute phase of a depression treatment protocol.

16 varying treatment parameters to optimize the treatment protocol.

17 pproach using ranibizumab and details of the treatment protocol.

18 ny significant benefit, independently of the treatment protocol.

19 ormally establish the merits of our proposed treatment protocol.

20 mes were not compromised by adherence to the treatment protocol.

21 and the outcome of our prospectively applied treatment protocol.

22 d tissue injury was minimal using a clinical treatment protocol.

23 Tests and models were stratified by treatment protocol.

24 treatment, 90 (74%) completed the specified treatment protocol.

25 ntensive BP-lowering or standard BP-lowering treatment protocols.

26 onsideration when contemplating prophylactic treatment protocols.

27 nerves was the main difference between the 2 treatment protocols.

28 administered by oral gavage on prevention or treatment protocols.

29 k of uniform patient populations and varying treatment protocols.

30 ehavior, prognosis, and response to specific treatment protocols.

31 g to current Children's Oncology Group (COG) treatment protocols.

32 gests that survival is improving with modern treatment protocols.

33 and pulmonary support were titrated based on treatment protocols.

34 avenous saline and insulin, similar to human treatment protocols.

35 treatment of uterine leiomyomas by using two treatment protocols.

36 ow the physicians to plan for more effective treatment protocols.

37 clinical trials and its inclusion in future treatment protocols.

38 evelopment of standardized multiple-modality treatment protocols.

39 re studies are needed that compare different treatment protocols.

40 and clinical toxicity associated with these treatment protocols.

41 terations and respond poorly to conventional treatment protocols.

42 strength to resin cement than other surface treatment protocols.

43 ferential diagnosis and test the efficacy of treatment protocols.

44 ical analyses for identifying robust optimal treatment protocols.

45 e degree of lung inflammation and cumbersome treatment protocols.

46 water or water alone in either prevention or treatment protocols.

47 herapy and the development of more efficient treatment protocols.

48 help in the development and optimization of treatment protocols.

49 o Pediatric Oncology Group Hodgkin's disease treatment protocols.

50 appeared to be similar in both of the L-NAME treatment protocols.

51 pressive disorder enrolled in 6 standardized treatment protocols.

52 weeks, before their entry into one of three treatment protocols.

53 L) treated on Pediatric Oncology Group (POG) treatment protocols.

54 lignant potential is desirable for choice of treatment protocols.

55 lycoamines was detected in both experimental treatment protocols.

56 timulation parameters for effective and safe treatment protocols.

57 these individuals do not respond to current treatment protocols.

58 treatment options, and to establish optimal treatment protocols.

59 ey are most likely to be cured with standard treatment protocols.

60 next generation TMS devices, experiments and treatment protocols.

61 essive treatment according to graft-specific treatment protocols.

62 e preservation using two different xenograft treatment protocols.

63 rats were given the following during a 2-wk treatment protocol: (1) candesartan cilexetil (AT1 recep

64 uction of peritransplantation rituximab into treatment protocols (4 of 62 immunotherapy recipients co

65 les of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P

66 line by emergency physicians, not reflecting treatment protocols according to the current guidelines.

67 objective evaluation of the effectiveness of treatment protocols, accuracy of staging and restaging m

68 Strikingly, in the treatment protocol administration of soluble VWAK and FY

69 Patients treated with standardized treatment protocol after cardiac arrest.

70 accrual of older persons to phase II and III treatment protocols after study initiation compared with

71 ting for other known risk factors, including treatment protocol, age, white blood cell count, DNA ind

72 By logistic regression with treatment, protocol, age, and gender as covariates, fema

73 Following treatment protocols, all rats underwent hyperinsulinemic

74 each) received combinations of the following treatment protocols: ALS, 0.5 ml on days -1 and 2; BM, 2

75 independent core laboratories blinded to the treatment protocol analyzed the angiographic and intrava

76 Seventy-one patients entered the transplant treatment protocol and 38 underwent liver transplantatio

77 Firstly, we established an acute treatment protocol and demonstrated this protocol could

78 tified analyses were performed to adjust for treatment protocol and known risk factors, and in the mo

79 ion, markedly extending survival in an early-treatment protocol and significantly though transiently

80 o placebo in individuals who comply with the treatment protocol and take medication.

81 bility of clinical oncologists to design new treatment protocols and analyze the response of patients

82 roenvironment with the potential to optimize treatment protocols and evaluate synergies between tumor

83 lications for designing effective antibiotic treatment protocols and for assessing the risks of antib

84 he potential to significantly improve trauma-treatment protocols and outcomes in hospital and prehosp

85 dy, which may lead to improved diagnosis and treatment protocols and reduce the incidence of acute bi

86 he COURAGE trial by nurse case managers with treatment protocols and resulted in significant improvem

87 e results may inform future childhood cancer treatment protocols and SMN surveillance guidelines for

88 have highlighted the interaction of specific treatment protocols and the immune environment on outcom

89 ge III retinoblastoma treated with a uniform treatment protocol, and as far as the authors are aware,

90 lled study inclusion and exclusion criteria, treatment protocol, and surveillance requirements, with

91 the emergence of viral resistance, demanding treatment protocols, and adverse side effects have expos

92 and severities of acute toxic effects across treatment protocols, and facilitate international resear

93 relation to trial arm, comorbid conditions, treatment protocols, and metastatic versus localized dis

94 Patients were not followed with uniform treatment protocols, and only limited information about

95 elarus and will enable improved diagnostics, treatment protocols, and prognostic decision-making.

96 medical contact-to-device time, coordinated treatment protocols, and regional data collection and re

97 us, as well as clinical practice guidelines, treatment protocols, and reimbursement policies.

98 in children, information regarding standard treatment protocols, and survival outcomes.

99 lammatory disease, carefully follow accepted treatment protocols, and teach youth comprehensive sexua

100 d to be used within the context of a defined treatment protocol; and f) no monitoring device, no matt

101 , and differences in severity of disease and treatment protocols; and measurement of different clinic

102 contexts including the study design details, treatment protocols, animal characteristics and conventi

103 The traumatic grief treatment protocol appears to be a promising interventio

104 Despite different treatment protocols applied to patients and use of diffe

105 le, well-described diagnostic guidelines and treatment protocols are essential: but often lacking.

106 inconclusive for many approaches, and clear treatment protocols are not available.

107 blishment and validation of hypoxia-directed treatment protocols are still under development, and it

108 e diagnosis of NPD and the evaluation of NPD treatment protocols, as well as for the study of ceramid

109 re based on cost of medications and costs of treatment protocols at our institutions.

110 Patients were randomized to treatment protocol based on intracranial pressure plus b

111 ervention group did not begin their assigned treatment protocol because of withdrawal of consent and

112 our DNA in patients assigned to one of three treatment protocols between May 8, 1993, and June 6, 201

113 nes are used in over 50% of childhood cancer treatment protocols, but their clinical usefulness is li

114 ad of skin carcinomas, however, the chemical treatment protocol caused ulcerous skin lesions, and 89%

115 these observations, we designed an improved treatment protocol combining plasmonic nanoantennae with

116 iatric oncologists have developed aggressive treatment protocols, combining surgery, craniospinal rad

117 ive assessable patients were enrolled onto a treatment protocol consisting of dexamethasone-containin

118 re studies of rats performed using a similar treatment protocol demonstrated greater reduction of glo

119 Moreover, the short-term treatment protocol described here provides a rapid and q

120 ell injection, whether using a prevention or treatment protocol design.

121 This MS-275 treatment protocol did not result in a redistribution of

122 The TNFalpha treatment protocols did not appear to produce any toxici

123 Two animals in the hypotensive treatment protocols died during the second and third ble

124 Mice in all treatment protocols displayed decreased vascular permeab

125 The modified treatment protocol effectively and safely prevented graf

126 n PA-treated rats, demonstrating that the PA treatment protocol effectively lowered ET-1 biosynthesis

127 ricted that even small changes in lesions or treatment protocols eliminate benefit, then the variabil

128 development pipelines, and biomarker-defined treatment protocols enabling personalization of medicine

129 Particularly in the late treatment protocol, ethyl gallate resulted in a lower he

130 are activated by the use of two distinctive treatment protocols followed by selective CO adsorption

131 The aim of this study was to develop a treatment protocol for (225)Ac-PSMA-617 alpha-radiation

132 uality evidence supporting a community-based treatment protocol for children with severe acute malnut

133 2 days postinfection, simulating a potential treatment protocol for DENV infection in humans.

134 ion and primary care, and incorporation of a treatment protocol for hospital services.

135 lation chemotherapy has been a long-standing treatment protocol for human neoplasia.

136 a novel non-invasive and non-pharmacological treatment protocol for neuropathic pain management, was

137 This study sought to 1) develop an efficient treatment protocol for postoperative automatic junctiona

138 A treatment protocol for the use of pulmonary artery cathe

139 Current treatment protocols for (177)Lu-labeled PSMA-617 therapi

140 drug target selection and the development of treatment protocols for a molecularly targeted therapy.

141 We have used identical treatment protocols for adults and children with small n

142 rent burn patients and to establish standard treatment protocols for burn pain.

143 odies have become incorporated into standard treatment protocols for cancer.

144 Doses used were based on optimized treatment protocols for each agent individually.

145 sions and to develop specific assessment and treatment protocols for each particular problem.

146 ent, there are no standardized diagnostic or treatment protocols for EATL.

147 nd to improve our prevention, diagnosis, and treatment protocols for future disasters.

148 CONCLUSION Current intensive treatment protocols for localized ESFT have erased the c

149 ture this parameter may be used to determine treatment protocols for lower calyceal stones.

150 al therapeutic approaches include randomized treatment protocols for multisystem disease.

151 ic companion study (CALGB 8461) to all CALGB treatment protocols for newly diagnosed adults with acut

152 ndation for the development of risk-specific treatment protocols for patients with CDH.

153 n be used to inform novel biologically based treatment protocols for patients with medulloblastoma.

154 well as the authors' specific prevention and treatment protocols for post-traumatic endophthalmitis,

155 Uncontrolled series of treatment protocols for severe Henoch-Schonlein purpura

156 ) are considered an integral part of current treatment protocols for the decontamination of titanium

157 Current treatment protocols for this condition are still unpredi

158 id therapy for anthrax must be considered in treatment protocols for this disease.

159 y, there is a pressing need to develop novel treatment protocols for this high-risk patient group.

160 then this may lead to selection criteria and treatment protocols for very early hypothermia in HIE at

161 pical clinical setting over a long duration, treatment protocols had marked heterogeneity, and substa

162 The same treatment protocols had no effect on AMCE cells derived

163 ration of these agents into transplant-based treatment protocols has improved outcomes.

164 ithium or ibudilast to existing chemotherapy treatment protocols has the potential to prevent chemoth

165 ma patients still exists, yet new methods of treatment protocol have been proposed for patients in tr

166 detect relapse acute myeloid leukemia (AML) treatment protocols have called for bone marrow exams ev

167 Complex patient factors and variability in treatment protocols have made it difficult to identify,

168 of the seven patients who have completed the treatment protocol (i.e., one or if necessary a second i

169 f intravenous artesunate (2.4 mg/kg) under a treatment protocol implemented by the Centers for Diseas

170 were examined for elements of trial design, treatment protocols, important biases, and major finding

171 study to evaluate a standardized endoscopic treatment protocol in a large cohort of patients with SP

172 Implementation of a mandatory treatment protocol in May 2003.

173 rons followed by secondary assays (i.e. post-treatment protocol in organotypic hippocampal slice cult

174 and 6MP were prognostic in the setting of a treatment protocol in which all treatment was coordinate

175 have been used under emergency compassionate-treatment protocols in human patients.

176 ge tissues undergoing apoptosis after cancer treatment protocols in humans.

177 nurses are more likely to initiate standard treatment protocols in situations such as the one report

178 th chronic periodontitis underwent different treatment protocols, in six groups: three FMD groups and

179 r contributing factors inherent in a group C treatment protocol included lack of central pathology re

180 lineated the current standard prevention and treatment protocols including intensive glycemic and blo

181 is an ongoing controversy on the benefits of treatment protocols, including dental lasers and photody

182 An integrated sepsis treatment protocol incorporating empirical antibiotics,

183 Contemporary, response stratified, treatment protocols incorporating dexamethasone have bee

184 e development of novel electrode designs and treatment protocols, increases in clinical success, defi

185 Treatment protocols increasingly stratify therapy accord

186 cal implementation of a comprehensive sepsis treatment protocol is feasible and is associated with ch

187 cheduling variant of the experimentally used treatment protocol is fragile (nonrobust) and (ii) disco

188 mized DELFIA procedure incorporating an acid treatment protocol is introduced for use with Eu(III)-DO

189 Our data suggest that this BM cell-based treatment protocol is safe, is well tolerated, and allow

190 eterrent to an otherwise extremely effective treatment protocol is the development in patients of loc

191 Eligibility for intensive AML treatment protocols is therefore typically based on age

192 In addition, differences in treatment protocols leave questions unanswered regarding

193 higher patient comprehension of the clinical treatment protocol, lower patient anxiety, higher patien

194 The type of graft and immune treatment protocol may influence the extent and reversib

195 Delayed treatment protocols may extend the window of opportunity

196 ng and treating physician as previously used treatment protocols may no longer provide the best patie

197 dition of the TRP-1-directed mAb TA99 to the treatment protocol mediated eradication of s.c. lesions.

198 ed statistical analysis adjusted for age and treatment protocol, MLL gene rearrangement was correlate

199 We propose that, to the extent that this treatment protocol more closely reflects clinical exposu

200 d with various combinations of the following treatment protocols: murine CTLA4-Ig, L-6 control Ig, si

201 ly as every 4 weeks based on a structured re-treatment protocol (n = 191 eyes).

202 NO is a useful adjunct to the postoperative treatment protocol of heart transplant patients with pul

203 iation criteria and treated according to the treatment protocol of the network were consecutively col

204 89 to infants enrolled in the evaluation and treatment protocol of the Wisconsin CF Neonatal Screenin

205 onto two sequential series of risk-adjusted treatment protocols of the Children's Cancer Group.

206 We examined the effect of the treatment protocol on antibodies to donor HLA, third-par

207 ch patients were assigned to one of the four treatment protocols on the basis of their exercise capac

208 We investigated the impact of two rapamycin treatment protocols on the major characteristics of alle

209 of the lacrimal artery or deviated from the treatment protocol (P = 0.035) and 14.3% for conventiona

210 with their respective groups in the singular treatment protocol (p<.05).

211 In a review of these modified treatment protocols, parent involvement is emphasized as

212 the data available vary too much in terms of treatment protocols, patient mix and symptom severity to

213 Here we used a new treatment protocol (Pc 26.1) in 16 thalassemia patients

214 r a novel, donor bone marrow (BM) cell-based treatment protocol ("Pittsburgh protocol").

215 plementation of a hospitalwide bronchiolitis treatment protocol promoting OU-HOT would affect hospita

216 The treatment protocol recommended either the immediate oral

217 This treatment protocol reduced metabolic disturbances in the

218 Modern treatment protocols rely on this information to tailor t

219 Broader implementation of sepsis treatment protocols represents a potential means for enh

220 ecin-PS conjugates appear most promising for treatment protocols requiring repeated washing after sen

221 The treatment protocol resulted in durable tumor responses i

222 ion of systemic low-dose IL-2 therapy to the treatment protocol resulted in the loss of the antitumor

223 The treatment protocols resulted in groups of animals that m

224 The treatment protocol results in PbS QD films exhibiting a

225 l quantitative parameters except PD for both treatment protocols showed statistically significant imp

226 years, all quantitative parameters for both treatment protocols showed statistically significant imp

227 ceived various combinations of the following treatment protocols: sirolimus, 1.5 mg/kg (3.0 mg/kg for

228 nical and basic research projects, including treatment protocol studies, acylcarnitine biomarker stud

229 ccurrences of deaths only in the hypotensive treatment protocols suggest that resuscitation to a targ

230 nt at 7 mo of age required a more aggressive treatment protocol than animals at 5.5 mo of age.

231 trial compared the response to a gingivitis treatment protocol that combined mechanical procedures a

232 A treatment protocol that combines myotoxicity with antiin

233 y, we circumvent this by introducing a novel treatment protocol that enables the preparation of high-

234 ter lung transplantation (LTx) and discuss a treatment protocol that has been developed at our instit

235 get to improve macrophage function in a late treatment protocol that improves sepsis survival.

236 We evaluated a treatment protocol that included matched transfusions, b

237 equires a highly structured approach using a treatment protocol that includes five essential componen

238 Tunicamycin, administered as part of a treatment protocol that inhibited glycosylation of all e

239 We designed a comprehensive treatment protocol that reduces the frequency and the se

240 Lastly, we introduce an improved treatment protocol that uses a lower rapamycin concentra

241 linary approach will provide a comprehensive treatment protocol that will increase the long-term viab

242 l length of stay implies adherence to strict treatment protocols that do not distinguish among differ

243 produce different conclusions about optimal treatment protocols that minimize resistance.

244 The development of treatment protocols that result in a complete response t

245 mortality risk should be reevaluated as new treatment protocols, therapeutic interventions, and moni

246 ransplants and describe the evolution of our treatment protocol to one that consists only of a brief

247 a randomized, double blind, sham controlled treatment protocol to study the effects of LFMS in a lar

248 his experience, we initiated a multimodality treatment protocol to treat patients with pelvic recurre

249 ospective drugs in intermittent and combined treatment protocols to cure T. cruzi infection initiated

250 Here, we utilized two treatment protocols to investigate whether rapamycin, co

251 outcomes have been described as well as new treatment protocols to provide a more effective therapy

252 ubicin with daunorubicin in childhood cancer treatment protocols to reduce cardiotoxicity should be a

253 ng children enrolled in one of our leukaemia treatment protocols, Total Therapy Study XII, prompted u

254 cids in the presence of blood simplifies pre-treatment protocols towards true point-of-care diagnosti

255 ded into the following four groups, based on treatment protocols: treatment with 40 mg/kg pravastatin

256 The treatment protocol used imaginal re-living of the death,

257 Nevertheless, when following the treatment protocol used in this trial among eyes with vi

258 The prevention protocol was extended and a treatment protocol used to examine if BMP-7 was benefici

259 -6)) that were independent of the risk group treatment protocol used.

260 Treatment protocols used in this study were well tolerat

261 A standard treatment protocol using rapid interhospital transfer fo

262 On October 2012, a treatment protocol using SAED was introduced after years

263 efficacy of SAP treatment, we used a delayed treatment protocol using SAP from day 7 to 13 only, and

264 This work also suggests that standard treatment protocols using BZ and NFX may be significantl

265 The development of clinical treatment protocols usually relies on evidence-based gui

266 A 2 stage NAM treatment protocol was applied.

267 lts with LL, an intensive pediatric-like ALL treatment protocol was associated with a good response r

268 The most effective treatment protocol was identified as activated MSC co-ad

269 Beginning in August 1997, a standardized treatment protocol was initiated for patients with suspe

270 of 199 mm3, which received the same combined treatment protocol, was significant at day 12 (P = 0.014

271 In the late treatment protocol, we administered ethyl gallate or nor

272 At the end of the treatment protocol, we assessed cardiac function using e

273 In the early treatment protocol, we infused P. aeruginosa until mean

274 Safety and feasibility of the tiered treatment protocol were confirmed.

275 d from 1970 to 1990 on two combined modality treatment protocols were identified.

276 ncer and Leukemia Group B (CALGB) front-line treatment protocols were prospectively studied for immun

277 Multiple treatment protocols were studied, including pre-ischemic

278 Four treatment protocols were tested: Chi220 monotherapy, CTL

279 Two separate experimental treatment protocols were used to examine the effect of s

280 e mice or from mice tolerized through either treatment protocol, were always able to prevent rejectio

281 his new information into the next-generation treatment protocols will unleash new challenges.

282 ar-old man who had ADC and completed a 12-wk treatment protocol with 1.2 mg/day of intranasal peptide

283 his is the first UK real-life study of a T&E treatment protocol with ranibizumab for exudative ARMD i

284 Novel treatment protocols with inclusion of antibodies and sma

285 in 50 HBeAg-negative patients under various treatment protocols with interferon alpha and/or nucleos

286 The development of treatment protocols with reduced toxicity and equivalent

287 e group seem superb, with histology-directed treatment protocols without radiation in both localized

288 rolonged overall survival when compared with treatment protocols without surgery (HR 7.26, 95% CI 3.4

289 component of continuation therapy in all ALL treatment protocols worldwide.